CLOs on the Move

Muse bio

www.musebio.com

 
Muse bio is transforming genome engineering by enabling, for the first time, high throughput massively-multiplexed CRISPR editing of proteins, pathways, and genomes. Through our powerful bioinformatics and novel molecular approach, ForgeCraft generates low-cost libraries of thousands of designer protein, pathway, or genome variants each with specifically defined, trackable mutations. This allows the impact of specific changes to be determined through rapid selection and high throughput screening allowing research timelines and costs to be reduced.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.musebio.com
  • 4001 Discovery Dr Suite N321, UCB 027
    Boulder, CO USA 80309

Executives

Name Title Contact Details

Similar Companies

Alta Medical Management

Alta Medical Management is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Beta Bionics

Beta Bionics is proud to be a Massachusetts public benefit corporation.

OWKIN

OWKIN builds mathematical models and algorithms that can interpret omics, visual data, biostatistics and patient profiles like never before. With OWKIN, patients directly benefit with more effective treatments.

CORRECT PHARMACY

CORRECT PHARMACY is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cerus

Cerus Corporation is dedicated solely to safeguarding the world`s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.